Abstract
Adjuvants are substances that boost the protective immune response to vaccine antigens. The majority of known adjuvants have been identified through the use of empirical approaches. Our aim was to identify novel adjuvants with well-defined cellular and molecular mechanisms by combining a knowledge of immunoregulatory mechanisms with an in silico approach. CD4+CD25+FoxP3+ regulatory T cells (Tregs) inhibit the protective immune responses to vaccines by suppressing the activation of antigen presenting cells such as dendritic cells (DCs). In this chapter, we describe the identification and functional validation of small molecule antagonists to CCR4, a chemokine receptor expressed on Tregs. The CCR4 binds the chemokines CCL22 and CCL17 that are produced in large amounts by activated innate cells including DCs. In silico identified small molecule CCR4 antagonists inhibited the migration of Tregs both in vitro and in vivo and when combined with vaccine antigens, significantly enhanced protective immune responses in experimental models.
Key words
- CCR4
- Regulatory T cell
- Adjuvant
- Small molecule
- Vaccine in silico
- Dendritic cells
This is a preview of subscription content, access via your institution.
Buying options

References
Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11:865–872
Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009) Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30:287–295
Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ et al (2008) In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A 105:10221–10226
Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK et al (2009) Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 4, e8084. doi:10.1371/journal.pone.0008084
Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E et al (2011) A CCR4 antagonist combined with vaccines induce antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 118:4853–4862
Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J et al (2012) Migratory and not lymphoid-resident dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood 120:1237–1245
Othy S, Topçu S, Kaveri SV, Bayry J (2012) Effect of CC chemokine receptor 4 antagonism on the evolution of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 109:E2412–E2413
Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J et al (2013) Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 133:98–107
Bosschem I, Bayry J, De Bruyne E, Van Deun K, Smet A, Vercauteren G et al (2015) Effect of different adjuvants on protection and side-effects induced by Helicobacter suis whole-cell lysate vaccination. PLoS One 10, e0131364. doi:10.1371/journal.pone.0131364
Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500
Ohkura N, Kitagawa Y, Sakaguchi S (2013) Development and maintenance of regulatory T cells. Immunity 38:414–423
Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM et al (2013) Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122:1419–1427
Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J (2012) Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. J Infect Dis 205:694–696
Gupta N, Hegde P, Lecerf M, Nain M, Kalia M, Vrati S et al (2014) Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells. Eur J Immunol 44:1363–1374
Maddur MS, Trinath J, Rabin M, Bolgert F, Guy M, Vallat JM et al (2015) Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cell Mol Immunol 12:650–652
Stephen-Victor E, Saha C, Sharma M, Holla S, Balaji KN, Kaveri SV et al (2015) Inhibition of programmed death 1 ligand 1 on dendritic cells enhances Mycobacterium-mediated interferon γ (IFN-γ) production without modulating the frequencies of IFN-γ-producing CD4+ T cells. J Infect Dis 211:1027–1029
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 105:10113–10118
Bayry J, Triebel F, Kaveri SV, Tough DF (2007) Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 178:4184–4193
Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P et al (2006) Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7:83–92
André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009) Surveillance of antigen-presenting cells by CD4+CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 174:1575–1887
Navarrete AM, Delignat S, Teillaud JL, Kaveri SV, Lacroix-Desmazes BJ (2011) CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. Vaccine 29:2649–2652
Navarrete AM, Meslier Y, Teyssandier M, André S, Delignat S, Triebel S et al (2009) CD4+CD25+ regulatory T cells modulate human dendritic cell chemokines by multiple mechanisms. Arthritis Rheum 60:2848–2849
Miyara M, Ito Y, Sakaguchi S (2014) TREG-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol 10:543–551
Bayry J, Gautier JF (2016) Regulatory T cell immunotherapy for Type 1 diabetes: a step closer to success? Cell Metab 23:231–233
Bayry J, Sibéril S, Triebel F, Tough DF, Kaveri SV (2007) Rescuing the CD4+CD25+ regulatory T cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 12:548–552
Maizels RM, Smith KA (2011) Regulatory T cells in infection. Adv Immunol 112:73–136
Bayry J (2014) Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy. Virusdisease 25:18–25
Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I et al (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 110:17945–17950
Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C et al (2012) Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 1:326–333
Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV (2005) Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol 175:7264–7273
Bayry J, Flower DR, Tough DF, Kaveri SV (2008) From ‘perfect mix’ to ‘potion magique’-regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nat Rev Microbiol 6:C1
Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F et al (2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194:847–853
Bayry J, Tartour E, Tough DF (2014) Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends Pharmacol Sci 35:163–165
Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM (1994) Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol 24:1743–1749
Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH (2007) Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67:6442–6450
Baele M, Decostere A, Vandamme P, Ceelen L, Hellemans A, Chiers K et al (2008) Isolation and characterization of Helicobacter suis sp. nov. from pig stomachs. Int J Syst Evol Microbiol 58:1350–1358
Liang J, De Bruyne E, Ducatelle R, Smet A, Haesebrouck F, Flahou B (2015) Purification of Helicobacter suis strains from biphasic cultures by single colony isolation: influence on strain characteristics. Helicobacter 3:206–216
Vriend G (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph 8:52–56, 29
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(33-38):27–38
Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr et al (2005) The Amber biomolecular simulation programs. J Comput Chem 2005(26):1668–1688
Price DJ, Brooks CL 3rd (2004) A modified TIP3P water potential for simulation with Ewald summation. J Chem Phys 121:10096–10103
Homer RW, Swanson J, Jilek RJ, Hurst T, Clark RD (2008) SYBYL line notation (SLN): a single notation to represent chemical structures, queries, reactions, and virtual libraries. J Chem Inf Model 48:2294–2307
Sadowski J (1997) A hybrid approach for addressing ring flexibility in 3D database searching. J Comput Aided Mol Des 11:53–60
Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV et al (2014) Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat Commun 5:4092. doi:10.1038/ncomms5092
Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L et al (2013) Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 5:172ra120
Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F et al (2007) B subunit of Shiga toxin-based vaccines synergize with {alpha} galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 179:3371–3379
Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D et al (2008) Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 31:101–112
O’Rourke JL, Solnick JV, Neilan BA (2004) Description of ‘Candidatus Helicobacter heilmannii’ based on DNA sequence analysis of 16S rRNA and urease genes. Int J Syst Evol Microbiol 54:2203–2211
Flahou B, Van Deun K, Pasmans F, Smet A, Volf J, Rychlik I et al (2012) The local immune response of mice after Helicobacter suis infection: strain differences and distinction with Helicobacter pylori. Vet Res 43:75. doi:10.1186/1297-9716-43-75
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25:402–408
Stolte M, Meining A (2001) The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15:591–598
Acknowledgements
M.N.D., D.R.F., D.F.T., and J.B. were affiliated to Edward Jenner Institute for Vaccine Research, University of Oxford, UK, when the work was initiated. Supported by the Institut National de la Santé et de la Recherche Médicale, Université Pierre et Marie Curie and Université Paris Descartes, Canceropole Ile de France, Agence Nationale de la Recherche, Ligue contre le Cancer, Association pour la Recherche sur le Cancer, Pole de compétitivité Medicen (Immucan) Centre d’investigation Clinique en Biothérapie (CIC-BT505), SIRIC-CARPEM and Labex Immuno-Oncology, France; European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement HEALTH-2010.2.4.5-2 ALLFUN; and the Indo-French Center for Promotion of Advanced Research (CEFIPRA, Reference No: 4803-1).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Davies, M.N. et al. (2017). In Silico Adjuvant Design and Validation. In: Fox, C. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 1494. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6445-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6445-1_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6443-7
Online ISBN: 978-1-4939-6445-1
eBook Packages: Springer Protocols